Movement Disorders - tevapharm.com
Teva is at the forefront of addressing these movement disorders through extensive research, development, and patient- centered initiatives. Our robust portfolio of treatments is designed to …
Teva Advances Pipeline of Movement Disorder Assets with …
SD-809 became part of Teva’s central nervous system (CNS) product portfolio with the acquisition of Auspex Pharmaceuticals in May 2015. Teva has numerous development programs in CNS focused …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® …
Nov 7, 2025 · About Teva Teva Pharmaceutical Industries Ltd. is a leading innovative biopharmaceutical company, enabled by a world-class generics business.
FDA Approves Teva's AUSTEDO® XR Once-Daily Tablets
Jun 6, 2024 · This development underscores Teva Pharmaceuticals' ongoing commitment to addressing the needs of patients with chronic movement disorders. How to obtain the latest research …
Tardive Dyskinesia (TD) Resources | AUSTEDO XR® (deutetrabenazine ...
Resources for each step of the treatment journey with AUSTEDO XR Teva is committed to supporting your patients with tardive dyskinesia (TD) and their care partners.
New Doses for Austedo XR Revolutionize Treatment Options for Movement …
Jun 3, 2024 · Final Thoughts The addition of new strengths for Austedo XR could mark a significant milestone in the treatment of movement disorders. With its convenient, once-daily dosing and …
Teva Advances Pipeline of Movement Disorder ... - Teva Pharmaceuticals
Jun 16, 2015 · About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to …
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in ...
Teva Pharmaceutical Industries Ltd. announced today that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients …
Teva Pharma announces long term efficacy and safety of …
Sep 24, 2024 · Teva Pharma announces long term efficacy and safety of deutetrabenazine in European patients with debilitating movement disorder tardive dyskinesia
Teva Advances Pipeline Of Movement Disorder Assets With
Jun 16, 2015 · SD-809 became part of Teva’s central nervous system (CNS) product portfolio with the acquisition of Auspex Pharmaceuticals in May 2015. Teva has numerous development programs in …